PARP2 and cancer: To evaluate whether FOXM1 is a valuable target, we analyzed the differential expression of FOXM1, PARP1, and PARP2 between cancer tissues and adjacent normal tissues in 31 cancers from the TCGA projects (Fig. 1A, B and Supplementary Fig. 1A, B).